Mirum Pharmaceuticals stock hits all-time high at $54.46

Mirum Pharmaceuticals (NASDAQ:MIRM) has achieved a new all-time high of $54.46 per share, reflecting strong investor confidence following robust Q1 2025 results where revenues surged 61% year-over-year to $111.6 million, significantly surpassing forecasts, largely driven by strong Livmarli sales. The company subsequently raised its full-year revenue guidance to $435-$450 million, prompting positive analyst reactions and increased price targets. This performance highlights Mirum's significant growth and strengthening position within the rare disease therapeutics market, even as InvestingPro analysis suggests the stock may be trading above its fair value.

Analysis

Mirum Pharmaceuticals (MIRM) has demonstrated significant operational momentum, culminating in its stock reaching a new all-time high of $54.46. This price appreciation is underpinned by robust financial performance, highlighted by first-quarter 2025 revenues of $111.6 million, which represents a 61% year-over-year increase and substantially beat analyst forecasts of $98.02 million. Growth is primarily driven by the strong commercial uptake of its key product, Livmarli, which generated $74 million in combined U.S. and international sales. Management has signaled confidence in sustained performance by raising its full-year revenue guidance to a range of $435-$450 million. This positive outlook is echoed by Wall Street, with analysts from H.C. Wainwright, JMP Securities, and Evercore ISI all issuing Buy/Outperform ratings and price targets ranging from $73 to $76, implying considerable upside from current levels. While the company's financial health appears solid, evidenced by a current ratio of 3.22, and its clinical pipeline is advancing with the VISTAS trial, a note of caution is warranted. The stock's 35.64% rise over the past year has led to a valuation that an InvestingPro analysis suggests may be above its calculated Fair Value, presenting a potential conflict between fundamental momentum and current market price.

Key Decisions for Investors

• Given the strong earnings beat, upwardly revised revenue guidance, and bullish analyst price targets, investors may consider the current strength a confirmation of the company's growth thesis in the rare disease market.
• Investors should weigh the positive operational momentum against the valuation concern, as the stock is at an all-time high and one analysis indicates it may be trading above fair value, suggesting a need for careful risk management or a disciplined entry strategy.
• Key catalysts to monitor for continued upside are the sustained sales trajectory of Livmarli, particularly the impact of its new tablet formulation, and the successful completion of enrollment for the VISTAS clinical trial for volixibat.